Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024
Eye scans detect signs of Parkinson’s up to 7 years before diagnosis Date 22 August 2023 Largest study on retinal imaging in Parkinson’s identifies markers of Parkinson’s in eye scans with the help of artificial intelligence (AI).
Researchers use AI to predict different drivers of Parkinson’s Date 17 August 2023 The AI examined images of brain cells and was able to identify changes in key areas of the cell that are characteristic of the different known mechanisms that cause Parkinson’s.
Clinical trial results offer hope of a new Parkinson’s treatment for motor symptoms and dyskinesia Date 7 July 2023 Updated trial results show NLX-112 could treat motor symptoms as well as dyskinesia. If further trials are successful, we could have a valuable new Parkinson’s drug by 2030.
Positive results from an early clinical trial for a drug boosting cell batteries in people with Parkinson’s Date 12 June 2023 Results from a UK phase 2 clinical trial show that ursodeoxycholic acid (UDCA) is safe for people with Parkinson's and can increase energy production in cells in the brain.
More research needed to investigate the impact of pesticides on brain cells in Parkinson’s Date 26 May 2023 More research needed to investigate the impact of pesticides on brain cells in Parkinson’s
Parkinson’s research needs you: help develop new treatments Date 19 May 2023 Development of new Parkinson’s treatments is only possible if everyone is part of the research process. We need your help to push promising research forward.
New lab test could help improve earlier diagnosis of Parkinson’s Date 13 April 2023 Latest study results show a new test could help diagnose Parkinson’s before damage occurs to brain cells.
Focused ultrasound shows promise as a Parkinson’s treatment in new study Date 30 March 2023 Results from a study of a technique known as focused ultrasound have shown a benefit for people with Parkinson’s with movement problems, for up to a year after treatment.
Early phase clinical trial results offer new hope for dyskinesia treatment Date 20 March 2023 An early phase clinical trial, funded by our supporters through the Parkinson's Virtual Biotech, suggests that the drug NLX-112 is safe and effective for people with Parkinson’s with levodopa-induced dyskinesias.
Study reveals benefits of physical activity for Parkinson’s symptoms Date 14 March 2023 Researchers compared results from over 150 studies to understand how different types of physical activity can be used to manage Parkinson’s symptoms.
